Found: Mini-transplants, also known as nonmyeloablative or reduced intensity transplants, make the benefits of stem

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will make an assessment of developing a cross-departmental strategy including the (a) Department for Science, Innovation and Technology and (b) NHS to (i) support and (ii) promote expertise in cell and gene therapy innovation.

Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department recognises that advanced cell and gene therapies will be an important part of the future of healthcare and the life sciences industry. The Department has been considering the recommendations of the National Cell and Gene Therapy Vision for the UK, a report published by the Cell and Gene Therapy Catapult in March 2022, and the UK Strategic Stem Cell Forum’s latest report, A 10 Year Vision for Stem Cell Transplantation and Advanced Cellular Therapies, published in July 2022. As part of this we have been conducting stakeholder engagement across the cell and gene therapy ecosystem to further understand the challenges raised and whether there is a role for the Department in coordinating activity in this area. We will continue to work with our public sector partners to ensure a whole system approach to advanced therapies, building on existing strengths to ensure a joined-up research, regulatory, and health ecosystem.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if she will review the (a) terms of reference and (b) governance of the UK Stem Cell strategic forum.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The terms of reference and governance of the UK Stem Cell Strategic Forum are reviewed periodically and on an ad hoc basis as required. The Forum published its latest report A 10 Year Vision for Stem Cell Transplantation and Advanced Cellular Therapies in July 2022 to address weaknesses in stem cell transplantation services. The Forum is working with the Department, NHS England, NHS Blood and Transplant, clinicians, industry, and representatives of patient groups to take the recommendations forward. An oversight committee and five working groups have been established in line with the current terms of reference.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential merits of increasing self-sufficiency in UK stem cell donations.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The UK Stem Cell Strategic Forum, a Departmental advisory body, has recommended in its report A 10 Year Vision for Stem Cell Transplantation and Advanced Cellular Therapies that donor to patient unrelated donations in the United Kingdom should be increased to 45%. This will improve the sustainability and resilience of UK stem cell supply, maintain the UK’s expertise in stem cell provision and support adoption of advanced cellular therapies. The Department is investing £2.4 million between April 2022 and March 2025 to recruit stem cell donors to improve resilience and help address health inequalities.

Found: In the stem cell transplantation project we have developed methods that enable us to grow human retinas

Found: on the Board of Anthony Nolan – a UK charity that works in the areas of leukaemia and hematopoietic stem

Found: references Abdelkefi A, Ben Jamil W, Torjman L , et al (2009) He mophagocy tic syndrome after hematopoietic stem

Found: on the Board of Anthony Nolan – a UK charity that works in the areas of leukaemia and hematopoietic stem

Found: on the Board of Anthony Nolan – a UK charity that works in the areas of leukaemia and hematopoietic stem

Found: on the Board of Anthony Nolan – a UK charity that works in the areas of leukaemia and hematopoietic stem

Found: ) report published in June 2022 which contains several recommendations for the UK in the areas of stem

Found: ) report published in June 2022 which contains several recommendations for the UK in the areas of stem

Found: cell transplantation (HSCT) service in Newcastle.

Found: first line treatment, options for next -line therapy are mainly guided by eligibility for autologous stem

Found: Fatal and other serious complicat ions can occur in patients who receive allogeneic haematopoietic stem

Found: Summary 2023-24 Quarter One'.The current system in place for Multiple Sclerosis (MS) Haematopoietic Stem